A new approach to second-line therapy for urothelial cancer?
Mené sur 48 patients atteints d'un cancer urothélial, de stade localement avancé ou métastatique, réfractaire aux sels de platine, cet essai canadien de phase II évalue, du point de vue de la réponse tumorale, l'efficacité de nanoparticules de paclitaxel lié à l'albumine
Despite responses shown by 40—60% of patients with advanced urothelial carcinoma receiving first-line cisplatin-based combination chemotherapy, disease progression occurs in nearly all patients at a median of about 8 months. Second-line agents are marginally active and yield responses of 5—20% and a median progression-free survival of only 3—4 months. No agents are approved by the US Food and Drug Administration in this setting, although taxanes are commonly used. Outside the USA, regulatory a ...
The Lancet Oncology , commentaire, 2012